4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the Neuro4D conference, Frankfurt, Germany, 13-14 May, 2019.
Alex Stevenson, 4D’s Chief Scientific Officer, commented, “We are excited to see these neuroprotective effects in preclinical models of Parkinson’s disease. Our aim is to develop a well-tolerated novel class of therapy that acts on the main disease pathologies and not only halts the progression of the disease but also reverses it.”
4D’s Research and Development team is giving a poster presentation entitled “Gut microbiome-derived bacterial strains have the ability to modulate neuroinflammation and neurodegeneration in Parkinson’s Disease models” on preclinical data from the Company’s lead Parkinson’s disease candidates, MRx0005 and MRx0029.
These two single-strain Live Biotherapeutic candidates were selected using 4D’s proprietary MicroRx® platform. They act in different but complementary ways, both relevant to Parkinson’s disease. MRx0005 exhibited neuroprotective effects in terms of reducing neuroinflammation in vitro and MRx0029 demonstrated the ability to protect against the loss of dopaminergic neurons (neurons that produce dopamine), in an industry-standard preclinical model.
4D pharma’s Dr Anna Ettorre, Senior Immunologist Team Leader, will give a presentation on the same subject, “From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson’s Disease models” at the Keystone Symposia: Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, USA on June 19.
A copy of the poster can be found at: https://www.4dpharmaplc.com/en/newsroom/posters-and-publications
